CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Robert R. Ruffolo Appointed at Nacuity Pharmaceuticals to its Board of Directors

Life Sciences Review Life Sciences Review | Monday, January 10, 2022
Tweet

Robert R. Ruffolo, Ph.D., joins Nacuity Pharmaceuticals’ Board of Directors.


FREMONT, CA: Nacuity Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing therapeutics for retinitis pigmentosa, cataracts, and other visual illnesses associated with oxidative stress, appoints Robert R. Ruffolo, Ph.D., to its Board of Directors. Dr. Ruffolo is an accomplished pharmaceutical executive with extensive expertise overseeing identifying, researching, and developing illness remedies.


"We are honored to have Dr. Ruffolo join our board. His expertise in scientific discovery, business strategy, and commercial development will be invaluable as we develop innovative solutions for patients who struggle with ocular diseases,' says Halden Conner, Chairman, CEO, and Co-Founder of Nacuity Pharmaceuticals Inc.


Dr. Ruffolo is currently employed with Versicolor Technologies as Chief Innovation Officer. From 2002 to 2008, he served as President of Research and Development and Senior Vice President of Wyeth Pharmaceuticals (now Pfizer). 


Before joining Wyeth, Dr. Ruffolo spent 17 years as Senior Vice President of Research and Development at SmithKline Beecham Pharmaceuticals (now GSK). He was instrumental in discovering and developing several commercially available products, including carvedilol, ropinerole, dobutamine, and eprosartan. Dr. Ruffolo has received numerous significant accolades, including the 2008 Discoverer's Award, for his pioneering work in discovering and developing carvedilol to treat congestive heart failure. Dr. Ruffolo is a Director at Sigilon Therapeutics, Elucida Oncology, Sapience Therapeutics, and Aridis Pharmaceuticals. Dr. Ruffolo earned a bachelor's degree in pharmacy and a doctorate in pharmacology from The Ohio State University.


“With its diverse library of novel antioxidant molecules, Nacuity is well-positioned to deliver treatments for ocular diseases caused by oxidative stress, including retinitis pigmentosa and cataracts,” says Dr. Ruffolo. “I’m delighted to join Nacuitys board to help support the team during this exciting time of clinical development and business growth.”


Weekly Brief

loading
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/robert-r-ruffolo-appointed-at-nacuity-pharmaceuticals-to-its-board-of-directors-nwid-560.html